Shopping Cart
Remove All
Your shopping cart is currently empty
Otelixizumab (Synonyms: TRX4, TRX 4, GSK-2136525, GSK2136525, ChAglyCD3)
Catalog No. T76754 Copy Product Info
🥰Excellent
Otelixizumab (ChAglyCD3) is a chimeric monoclonal antibody targeting CD3, used in research on Type 1 diabetes and autoimmune diseases.
Otelixizumab
Copy Product Info🥰Excellent
Catalog No. T76754
Synonyms TRX4, TRX 4, GSK-2136525, GSK2136525, ChAglyCD3
Otelixizumab (ChAglyCD3) is a chimeric monoclonal antibody targeting CD3, used in research on Type 1 diabetes and autoimmune diseases.
Otelixizumab
Cas No. 881191-44-2
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $169 | In Stock | In Stock | |
| 5 mg | $448 | In Stock | In Stock | |
| 10 mg | $715 | - | In Stock | |
| 25 mg | $1,080 | - | In Stock | |
| 50 mg | $1,460 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.13% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Otelixizumab (ChAglyCD3) is a chimeric monoclonal antibody targeting CD3, used in research on Type 1 diabetes and autoimmune diseases. |
| In vitro | Methods: Isolated intrinsic monocyte layer (LPMC) and mucosal tissue explants were incubated with Otelixizumab for 24-48 hours. The production of inflammatory cytokines was determined by enzyme-linked immunosorbent assay. Results: Incubation of LPMC with Otelixizumab reduced the production of interferon gamma, interleukin (IL) -17A, and other inflammatory cytokines and chemokines, while increasing the production of IL-10.[1] |
| In vivo | Human CD3ε chain (nod-HUCdε) transgenic mice treated with Otelixizumab (50 μg/ day, 5 days, intravenously) experienced remission of diabetes symptoms in 47% of mice.[2] |
| Synonyms | TRX4, TRX 4, GSK-2136525, GSK2136525, ChAglyCD3 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CD3 |
| Molecular Weight | 144.58 kDa |
| Cas No. | 881191-44-2 |
| Isotype | Human IgG1 lambda2 |
| Recommended Isotype Control |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Preview
Related Tags: buy Otelixizumab | purchase Otelixizumab | Otelixizumab cost | order Otelixizumab | Otelixizumab in vivo | Otelixizumab in vitro | Otelixizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.